Status:
COMPLETED
Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib
Lead Sponsor:
GlaxoSmithKline
Conditions:
Hepatitis B
Eligibility:
All Genders
7-9 years
Phase:
PHASE4
Brief Summary
Persistence of seroprotective antibody concentrations \& immunological memory shown by the ability to mount a response to a challenge dose of HBV vaccine
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- A male or female aged 7 to 9 years at the time of study entry .
- Subjects who have received a total of 4 doses of DTPa-HBV-IPV/Hib vaccine or a total of 4 doses of HBV vaccine in previous vaccination studies.
- Evidence of previous hepatitis B booster vaccination or disease since administration of the fourth dose of DTPa-HBV-IPV/Hib or HBV vaccine.
Exclusion
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT00356564
Start Date
July 1 2006
End Date
December 1 2006
Last Update
October 12 2016
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Ettenheim, Baden-Wurttemberg, Germany, 77955
2
GSK Investigational Site
Kehl, Baden-Wurttemberg, Germany, 77694
3
GSK Investigational Site
Oberkirch, Baden-Wurttemberg, Germany, 77704
4
GSK Investigational Site
Offenburg, Baden-Wurttemberg, Germany, 77654